Fig. 1

Tofo ameliorates the impairment in glucose metabolism and skeletal muscle loss during the development of diet-induced obesity. (A) Schematic diagram of the experiment. Male C57BL/6 were put on a NC, HFD+Saline, or HFD+Tofo for 12 weeks. Oral glucose tolerance test (OGTT) and insulin tolerance test (ITT) were performed after 10 weeks of diet, cardiotoxin (CTX) was injected to skeletal muscle to induce acute injury after 11 weeks of diet, and after one week of recovery, mice were sacrificed and analyzed. (B) OGTT and AUC (NC = 10; HFD+Saline = 14; HFD+Tofo = 14). (C) ITT (NC = 10; HFD+Saline = 14; HFD+Tofo = 14). (D) Body weight (grams) at the time of sacrifice (NC = 10; HFD+Saline = 10; HFD+Tofo = 10). (E) Liver weight (grams) (NC = 10; HFD+Saline = 10; HFD+Tofo = 10). (F, G) Skeletal muscle percentage, tissue weight to the total body weight, tibialis anterior (TA), gastrocnemius (GC) (NC = 10; HFD+Saline = 10; HFD+Tofo = 10). Data represent mean ± SEM. Statistical analysis was performed using two-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001) for OGTT and ITT (NC vs HFD = *; NC vs HFD+Tofo = a; HFD vs HFD+Tofo = #). Data represent mean ± SEM. Statistical analysis for other figures were performed using one-way ANOVA (*p < 0.05, **p < 0.01, ***p < 0.001).